(FDMT) 4D Molecular Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001
FDMT: Genetic, Medicines, Eye, Heart, Lung
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage biotherapeutics company specializing in genetic medicines. Utilizing its proprietary therapeutic vector evolution platform, the firm develops innovative treatments across ophthalmology, cardiology, and pulmonology. This platform enables the creation of tailored viral vectors for enhanced gene delivery, setting it apart in the competitive landscape of genetic medicine.
The companys pipeline includes several candidates in various clinical phases. 4D-150 is in Phase 1/2 trials for wet age-related macular degeneration and diabetic macular edema. 4D-125 targets X-linked retinitis pigmentosa, while 4D-110 addresses choroideremia, both in Phase 1/2 trials. 4D-710 focuses on cystic fibrosis, and 4D-310 on Fabry disease cardiomyopathy, each in Phase 1/2. Pre-clinical stages include 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency.
Collaborations with Arbor Biotechnologies, Astellas Gene Therapies, uniQure Biopharma, and the Cystic Fibrosis Foundation underscore 4D Moleculars commitment to innovation and partnerships. Founded in 2013, the company is headquartered in Emeryville, California, with operations in the Netherlands and the U.S.
3-Month Forecast: Indicators suggest a bearish outlook. The stock price is below SMA 20 and 50, with SMA 200 at $12.68, indicating a downtrend. Moderate volatility (ATR 0.44) and negative RoE (-25.95) signal potential decline, possibly stabilizing near $3.50-$4.00. Investors should monitor technical support levels and company news for potential shifts.
Additional Sources for FDMT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
FDMT Stock Overview
| Market Cap in USD | 192m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2020-12-11 |
FDMT Stock Ratings
| Growth 5y | -79.4% |
| Fundamental | - |
| Dividend | 0.0% |
| Rel. Strength Industry | -84.9 |
| Analysts | 4.08/5 |
| Fair Price Momentum | 3.38 USD |
| Fair Price DCF | - |
FDMT Dividends
No Dividends PaidFDMT Growth Ratios
| Growth Correlation 3m | -79.8% |
| Growth Correlation 12m | -98.2% |
| Growth Correlation 5y | -51.4% |
| CAGR 5y | -41.59% |
| CAGR/Max DD 5y | -0.45 |
| Sharpe Ratio 12m | -1.60 |
| Alpha | -92.88 |
| Beta | 0.41 |
| Volatility | 77.97% |
| Current Volume | 310.6k |
| Average Volume 20d | 639.4k |
As of March 15, 2025, the stock is trading at USD 4.11 with a total of 310,605 shares traded.
Over the past week, the price has changed by +0.98%, over one month by -15.78%, over three months by -36.57% and over the past year by -86.01%.
No, based on ValueRay Analyses, 4D Molecular Therapeutics (NASDAQ:FDMT) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -79.37 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FDMT as of March 2025 is 3.38. This means that FDMT is currently overvalued and has a potential downside of -17.76%.
4D Molecular Therapeutics has received a consensus analysts rating of 4.08. Therefor, it is recommend to buy FDMT.
- Strong Buy: 5
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, FDMT 4D Molecular Therapeutics will be worth about 3.7 in March 2026. The stock is currently trading at 4.11. This means that the stock has a potential downside of -10.46%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 34 | 727.3% |
| Analysts Target Price | 45.4 | 1004.6% |
| ValueRay Target Price | 3.7 | -10.5% |